Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 2/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29211171 | 0.77 | SLC22A6 (0.41) | SLC22A6TSHRTDP1SMN1; SMN2FOLH1 | |
| SCHEMBL1704335 | 0.73 | SLC22A6 (0.38) | SLC22A6TSHRTDP1SMN1; SMN2FOLH1 | |
| SCHEMBL28719269 | 0.73 | SLC22A6 (0.38) | SLC22A6TSHRTDP1SMN1; SMN2FOLH1 | |
| SCHEMBL1271508 | 0.73 | SLC22A6 (0.38) | SLC22A6TSHRTDP1SMN1; SMN2FOLH1 | |
| SCHEMBL16014762 | 0.71 | — | — | |
| SCHEMBL25288474 | 0.68 | SLC22A6 (0.33) | SLC22A6TDP1SMN1; SMN2FOLH1 | |
| SCHEMBL7599047 | 0.67 | CYP2D6 (0.33) | SLC22A6TSHRTDP1SMN1; SMN2FOLH1 | |
| SCHEMBL7598977 | 0.67 | THRB (0.41) | SLC22A6TDP1SMN1; SMN2FOLH1ACLY | |
| SCHEMBL30979237 | 0.67 | THRB (0.41) | SLC22A6TDP1SMN1; SMN2FOLH1 | |
| Acetic Acid SCHEMBL4276426 | 0.66 | FFAR3 (0.44) | TSHRTDP1ACLYLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047836-A | Preparation method of goserelin impurity E | 中肽生化有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-118047836-A | Preparation method of goserelin impurity E | 中肽生化有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-109701013-B | Targeted nano drug delivery system and preparation method thereof | 安徽工程大学 | 2021-07-13 | — | — | CN | disclosed |
| US-9598466-B2 | Glycopeptide constructs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2368561-B1 | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response | UNIV CALIFORNIA (US) | 2013-12-04 | — | — | EP | disclosed |
| US-20130295042-A1 | Peptides and Peptide Mimetics to Treat Pathologies Associated With Eye Disease | UAB RESEARCH FOUNDATION | 2013-11-07 | — | — | US | disclosed |
| US-8568766-B2 | Peptides and peptide mimetics to treat pathologies associated with eye disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-29 | — | — | US | disclosed |
| US-8569452-B2 | Preparation of phalloidin and its derivatives | AMERICAN PEPTIDE COMPANY, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120214968-A1 | Preparation of phalloidin and its derivatives | BACHEM AMERICAS, INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120004720-A1 | G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES | THE UNIVERSITY OF ALABAMA (US) | 2012-01-05 | — | — | US | disclosed |
| US-20080293639-A1 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080095821-A1 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1890715-A2 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-27 | — | — | EP | disclosed |
| CN-101065137-A | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies | UNIV CALIFORNIA (US) | 2007-10-31 | — | — | CN | disclosed |
| EP-1799242-A2 | G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES | The Regents of the University of California (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070032430-A1 | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-02-08 | — | — | US | disclosed |
| WO-2006118805-A9 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE | UNIV CALIFORNIA (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006118805-A2 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060205669-A1 | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-09-14 | — | — | US | disclosed |
| WO-2006034056-A2 | G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130295042-A1 | Peptides and Peptide Mimetics to Treat Pathologies Associated With Eye Disease | APOB, IAPP, APOL1 | SLC22A6 2247/4885TSHR 2420/4885TDP1 3233/4885 |
| US-20080095821-A1 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE | APOB, APOL1, GLP1R | SLC22A6 3578/4885TSHR 3318/4885TDP1 2980/4885 |
| US-20060205669-A1 | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies | APOB, CCL2, GLP1R | SLC22A6 3881/4885TSHR 3375/4885TDP1 2259/4885 |
| US-20070032430-A1 | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response | APOB, APOL1, GLP1R | SLC22A6 3578/4885TSHR 3318/4885TDP1 2980/4885 |
| US-20120004720-A1 | G-TYPE PEPTIDES AND OTHER AGENTS TO AMELIORATE ATHEROSCLEROSIS AND OTHER PATHOLOGIES | APOB, CCL2, GLP1R | SLC22A6 3881/4885TSHR 3375/4885TDP1 2259/4885 |
| US-20080293639-A1 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE | APOB, APOL1, GLP1R | SLC22A6 3578/4885TSHR 3318/4885TDP1 2980/4885 |
| US-20120214968-A1 | Preparation of phalloidin and its derivatives | ACTB, ACTR3, ACTR5 | SLC22A6 3222/4885TSHR 2347/4885TDP1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.